Drug Trial Radar · NCT07497074
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Oct 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.
Conditions
- Cervical Cancer
Interventions
JSKN033Drug
JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol
PlatinumDrug
JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol
BevacizumabDrug
JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: 21 days from the first dose
- Frequency and severity of Treatment-Related Adverse Events (TRAEs)Time frame: 21 days from the first dose
- Frequency and severity of Serious Adverse Events (SAEs)Time frame: 21 days from the first dose
- Objective Response Rate (ORR) as assessed by the investigator and IRC per RECIST 1.1.Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.